Not yet filed. No Q3 2026 Form 13F from Avoro Capital Advisors has been detected on SEC EDGAR yet. The deadline for the quarter ended Sep 30, 2026 is Monday, Nov 16, 2026.
From the fund's 2026 Q2 Form 13F (filed Aug 14, 2026) — the latest quarter fully processed on this site.
| Stock | Shares | Portfolio weight |
|---|---|---|
| UTHR · UNITED THERAPEUTICS Corp | 2,777,777 | 13.52% |
| ASND · Ascendis Pharma A/S | 5,111,111 | 12.24% |
| KRYS · Krystal Biotech, Inc. | 2,888,888 | 9.64% |
| MDGL · MADRIGAL PHARMACEUTICALS INC | 1,833,333 | 8.84% |
| ARGX · ARGENX SE - ADR | 1,000,000 | 8.33% |
| ARWR · ARROWHEAD PHARMACEUTICALS, INC. | 11,355,555 | 8.31% |
| KYMR · KYMERA THERAPEUTICS INC | 7,474,747 | 7.70% |
| RVMD · REVOLUTION MEDICINES INC | 2,297,000 | 3.86% |
| CYTK · CYTOKINETICS INC | 4,999,999 | 3.82% |
| CELC · Celcuity Inc. | 3,400,000 | 3.19% |
Largest increase 2026 Q1 → 2026 Q2: VRDN (+66.7% of shares). New position in 2026 Q2: ASND (12.24% of the portfolio). Largest trim 2026 Q1 → 2026 Q2: LXEO (-20.6% of shares). Exited in 2026 Q2: ALKS, ASND, CELC and 2 more.
Full record: Avoro Capital Advisors fund page · manager profile & 13F-clone record · Q3 2026 season tracker.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.